Clovis Oncology Rucaparib PARP Inhibitor Ovarian Cancer BRCA Clinical Data

Pooled analysis of clinical efficacy and safety data for rucaparib, a PARP inhibitor, in BRCA-mutant high-grade ovarian carcinoma patients. Study combines data from two Phase 2 trials (Study 10 and ARIEL2) evaluating rucaparib 600 mg twice daily in patients with prior chemotherapy exposure.